Compartir
array:22 [ "pii" => "S0025775300716253" "issn" => "00257753" "doi" => "10.1016/S0025-7753(00)71625-3" "estado" => "S300" "fechaPublicacion" => "2000-01-01" "aid" => "71625" "copyright" => "Elsevier España, S.L.. Todos los derechos reservados" "copyrightAnyo" => "2000" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2000;115:561-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 5817 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 5456 "PDF" => 354 ] ] "itemSiguiente" => array:18 [ "pii" => "S0025775300716265" "issn" => "00257753" "doi" => "10.1016/S0025-7753(00)71626-5" "estado" => "S300" "fechaPublicacion" => "2000-01-01" "aid" => "71626" "copyright" => "Elsevier España, S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2000;115:564-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1617 "formatos" => array:3 [ "EPUB" => 6 "HTML" => 1461 "PDF" => 150 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Marcadores predictivos de progresión a sida en niños infectados por transmisión vertical por el virus de la inmunodeficiencia humana tipo 1" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "564" "paginaFinal" => "567" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Prognostic markers of progression to aids in infants vertically infected by human immunodeficiency virus type-1" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Salvador Resino, José M.<span class="elsevierStyleSup">a</span> Bellóon, Dolores Gurbindo, José Tomás Ramos, Jesús Ruiz Contreras, M.<span class="elsevierStyleSup">a</span> Ángeles Muñoz-Fernández" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Salvador" "apellidos" => "Resino" ] 1 => array:2 [ "nombre" => "José M.<span class="elsevierStyleSup">a</span>" "apellidos" => "Bellóon" ] 2 => array:2 [ "nombre" => "Dolores" "apellidos" => "Gurbindo" ] 3 => array:2 [ "nombre" => "José" "apellidos" => "Tomás Ramos" ] 4 => array:2 [ "nombre" => "Jesús" "apellidos" => "Ruiz Contreras" ] 5 => array:2 [ "nombre" => "M.<span class="elsevierStyleSup">a</span>" "apellidos" => "Ángeles Muñoz-Fernández" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775300716265?idApp=UINPBA00004N" "url" => "/00257753/0000011500000015/v1_201307291747/S0025775300716265/v1_201307291747/es/main.assets" ] "es" => array:14 [ "idiomaDefecto" => true "titulo" => "Levofloxacino oral frente a ceftriaxona y a amoxicilina/ácido clavulánico intravenosos en el tratamiento de la neumonía adquirida en la comunidad que requiere hospitalización" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "561" "paginaFinal" => "563" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Verónica Kalbermatter, Daniel Bagilet, Mario Diab, Eduardo Javkin" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Verónica" "apellidos" => "Kalbermatter" ] 1 => array:4 [ "nombre" => "Daniel" "apellidos" => "Bagilet" "email" => array:1 [ 0 => "bagilet@ciudad.com.a" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 2 => array:2 [ "nombre" => "Mario" "apellidos" => "Diab" ] 3 => array:2 [ "nombre" => "Eduardo" "apellidos" => "Javkin" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "<span class="elsevierStyleItalic">Servicio de ClÍnica Médica. Sanatorio Delta. Rosario. Argentina.</span>" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "*" "correspondencia" => "Correspondencia: Dr. D. Bagilet. Zelaya, 1.536. 2000 Rosario. Argentina. Correo" ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Levofloxacin versus ceftriaxone and intravenous amoxicillin/clavulanate in the treatment of community-acquired pneumonia that require hospitalization" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2000-04-06" "fechaAceptado" => "2000-09-05" "PalabrasClave" => array:1 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec223107" "palabras" => array:4 [ 0 => "Neumonía adquirida en la comunidad" 1 => "Levofloxacino" 2 => "Ceftriaxona" 3 => "Amoxicilina/ácido clavulánico" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<span class="elsevierStyleSectionTitle">Fundamento</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Recientemente fue introducido en el mercado farmacéutico el levofloxacino, un antibiótico de la familia de las quinolonas que se utiliza con éxito en el tratamiento ambulatorio de los pacientes con neumonía adquirida en la comunidad. El objetivo de este trabajo fue comparar la efectividad y tolerancia del levofloxacino oral frente a la ceftriaxona y a la amoxici-lina/ácido clavulánico intravenosos en el tratamiento de las neumonías adquiridas en la comunidad que requieren hospitalización.</p> <span class="elsevierStyleSectionTitle">Pacientes y método</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">En este trabajo prospectivo y aleatorizado se incorporaron 84 pacientes, 28 por grupo, de ambos sexos con neumonía adquirida en la comunidad que requiere hospitalización. Los mismos fueron asignados al azar para recibir uno de los siguientes tratamientos: amo-xicilina/ácido clavulánico, 1/0,2 g intravenosos cada 8 h, ceftriaxona, 1 g intravenoso cada 12 h o levofloxacino, 500 mg por vía oral cada 24 h. En el momento del ingreso se registraron las características clínicas, bioquímicas y radiológicas de cada caso, y a las 72 h se evaluó la respuesta al tratamiento mediante la evolución de la curva térmica y de las imágenes radiológicas. Las variables cuantitativas fueron analizadas con ANOVA, las cualitativas con el test de la χ2 y corrección de Yates. El nivel de significación propuesto fue de α = 0,05.</p> <span class="elsevierStyleSectionTitle">Resultados</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">La edad, el sexo, la presentación clínica, las mediciones bioquímicas y las imágenes radiológicas en los tres grupos fueron similares y no se registraron efectos adversos en ninguno de ellos. El número de pacientes con respuestas favorables en los grupos amoxicilina/ácido clavulánico, ceftriaxona y levofloxacino fue de 25 (89%), 25 (89%) y 26 (93%), respectivamente; p = 0,870.</p> <span class="elsevierStyleSectionTitle">Conclusiones</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">El levofloxacino es una opción terapéutica simple, efectiva y segura para los pacientes con neumonía adquirida en la comunidad que requieren hospitalización.</p>" ] "en" => array:1 [ "resumen" => "<span class="elsevierStyleSectionTitle">Background</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Levofloxacin, an antibiotic from the quinolone family, which is used with success in the ambulatory treatment of patients with community-acquired pneumonia, has been recently introduced to the pharmaceutical market. The purpose of this study was to compare the effectiveness and tolerance of oral (v.o.) levofloxacin (LVF) versus intravenous (i.v.) amoxicillin/clavula-nate (AMX/CL) and ceftriaxone (CTX) in the treatment of the community-acquired pneumonia that require hospitalization (CAPH).</p> <span class="elsevierStyleSectionTitle">Patients and method</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">In this prospective and randomized study 84 patients were included, 28 per group, from both sex with CAPH. The patients were assigned randomly to receive one of the next treatments: AMX/CL, 1.02 g i.v. every 8 h, CTX, 1 g i.v. every 12 h or LVF, 500 mg v.o. every 24 h. At the beginning clinical, biochemical and radiological characteristics were recorded from each case and at the 72 h the effect of treatment was evaluated using the evolution of the thermal curve and radiological images. The quantitative variables were analized with ANOVA, the qualitatives parameters with χ2 test and Yates correction. The level of signification was α = 0.05.</p> <span class="elsevierStyleSectionTitle">Results</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Age, sex, clinical presentation, biochemical measurements and radiological images in the 3 groups were similar and no adverse effects were recorded in any of them. Number of pa-tients with favorable outcome in the groups AMX/CL, CTX and LVF was 25 (89%), 25 (89%) and 26 (93%); p = 0,870.</p> <span class="elsevierStyleSectionTitle">Conclusions</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Levofloxacin can be a simple, effective and safe therapeutic option for patients with CAPH.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Referencias Bibliograficas" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:9 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R. Davis" 1 => "H.M. Bryson" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Drugs" "fecha" => "1994" "volumen" => "47" "paginaInicial" => "667" "paginaFinal" => "700" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacokinetic profile of levofloxacin following once-daily 500 mg. oral or intravenous." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.C. Chien" 1 => "M.C. Rogge" 2 => "L.G. Gisclon" 3 => "C. Curtin" 4 => "F. Wong" 5 => "J. Natarajan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "1997" "volumen" => "41" "paginaInicial" => "2256" "paginaFinal" => "2260" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9333057" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "clinical pharmacokinetics of levofloxacin." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D.M. Fish" 1 => "A.T. Chow" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2165/00003088-199732020-00002" "Revista" => array:6 [ "tituloSerie" => "Clin Pharmacokinet" "fecha" => "1997" "volumen" => "32" "paginaInicial" => "101" "paginaFinal" => "119" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9068926" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ortho Pharmaceutical Corporation and Mac Neil Pharmaceutical Once a day Levaquin tablets injection. Product information. Raritan, NJ, EE.UU. 09969-0602." ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "H.D. Langtry" 1 => "H.M. Lamb" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "1998" "volumen" => "56" "paginaInicial" => "487" "paginaFinal" => "515" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9777318" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Commentary on the 1993 American Thoracic Society Guidelines for the treatment of community-acquired pneumonia." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "D. Campell" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Chest" "fecha" => "1999" "volumen" => "115" "paginaInicial" => "S14" "paginaFinal" => "S18" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predicting death in patients hospitalized for community-acquired pneumonia." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "B.M. Farr" 1 => "A. Sloman" 2 => "M.J. Fish" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "1991" "volumen" => "115" "paginaInicial" => "428" "paginaFinal" => "436" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/1872491" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "prediction rule to identify low-risk patients with community-acquired pneumonia." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.J. Fine" 1 => "T.E. Auble" 2 => "D.M. Yearly" 3 => "B.H. Hanusa" 4 => "L.A. Weissfeld" 5 => "D.E. Singer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199701233360402" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1997" "volumen" => "336" "paginaInicial" => "243" "paginaFinal" => "250" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8995086" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of community-acquired pneumonia IDSA guidelines." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.M. Berstein" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Chest" "fecha" => "1999" "volumen" => "115" "paginaInicial" => "S9" "paginaFinal" => "S13" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/00257753/0000011500000015/v1_201307291747/S0025775300716253/v1_201307291747/es/main.assets" "Apartado" => array:4 [ "identificador" => "24087" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Original breve" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/00257753/0000011500000015/v1_201307291747/S0025775300716253/v1_201307291747/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775300716253?idApp=UINPBA00004N" ]
